New hope for kidney transplant patients: cholesterol drug evolocumab shows promise
NCT ID NCT04608474
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested the drug evolocumab (Repatha) in 81 kidney transplant recipients with high cholesterol. The goal was to see if it could safely lower cholesterol levels, since standard statin drugs often cause side effects in these patients. The results could lead to a better way to manage heart disease risk after a kidney transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evolocumab (Repatha)
What this could lead to
If successful, this could provide a safer cholesterol-lowering option for kidney transplant patients, reducing their heart disease risk.
What could go wrong
This is a small pilot study with only 81 participants, so results may not apply to everyone. The drug's long-term safety in transplant recipients is still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States